Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • Telemedicine BW
    • MDR & IVDR

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 04/11/2020

    Which treatment is best for childhood brain tumors? Global trial receives funding of EUR 2.2m

    The German Childhood Cancer Foundation is providing EUR 2.2m to fund the phase III clinical trial to investigate the treatment options for certain types of childhood brain cancer with a chronic course. Initiated by the Hopp Children’s Cancer Center Heidelberg, the trial will compare two standard chemotherapy treatments and a targeted therapy to establish which is the most effective and well tolerated as a standard therapy for young patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/welche-behandlung-ist-die-beste-bei-hirntumoren-im-kindesalter-weltweite-studie-wird-mit-22-mio-euro-gefoerdert
  • Article - 04/11/2020 Analysegerät und Kartusche

    Rapid coronavirus test delivers results in 43 minutes

    The Hahn-Schickard Institute and Spindiag GmbH in Freiburg im Breisgau have joined forces to develop a rapid test used at the point of care. The test takes just 43 minutes to show whether a patient is infected with the coronavirus SARS-CoV-2. The rapid test is expected to be given market approval in Germany and the EU during the final quarter of 2020.

    https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-coronavirus-test-delivers-results-43-minutes
  • Press release - 02/11/2020

    CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the safety, reactogenicity and immunogenicity of CVnCoV, its investigational SARS-CoV-2 vaccine candidate.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-reports-positive-interim-phase-1-data-its-covid-19-vaccine-candidate-cvncov
  • Press release - 02/11/2020

    Juvenile myelomonocytic leukemia: International classification model allows for customized treatment

    Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of early childhood. Previous research activities have shown that JMML patients can be divided into three groups based on certain genetic markers, DNA methylation. Depending on the subgroup, statements can be made about the course of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/juvenile-myelomonocytic-leukemia-international-classification-model-allows-customized-treatment
  • Inside the fight against COVID-19 - 28/10/2020 Apogenix_Asunercept_COVID-19_Teaser.png

    A new immunotherapeutic agent for treating severe COVID-19 cases

    Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-immunotherapeutic-agent-treating-severe-covid-19-cases
  • Press release - 26/10/2020

    How to prevent the spread of tumor cells via the lymph vessels

    What role do the lymphatic vessels play in the metastasis of cancer cells? Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg developed a method to investigate this question in mice. The aim of the work was to identify new ways to block the dangerous colonization and spread of tumor cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-prevent-spread-tumor-cells-lymph-vessels
  • Press release - 23/10/2020

    CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in mice and hamsters.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-reports-positive-preclinical-data-its-covid-19-vaccine-candidate-cvncov
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial – with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Press release - 20/10/2020

    EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

    The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
  • Press release - 15/10/2020

    Pancreatic cancer: Subtypes with different aggressiveness discovered

    Tumors of the pancreas are particularly feared. They are usually discovered late and mortality is high. Until now, no targeted and personalized therapies exist. Scientists at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine* (HI-STEM) have now succeeded for the first time in defining two differently aggressive molecular subtypes of pancreatic carcinoma.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pancreatic-cancer-subtypes-different-aggressiveness-discovered
  • Press release - 15/10/2020

    Common Vulnerabilities of Coronaviruses

    International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/common-vulnerabilities-coronaviruses
  • Intestinal peptide heals lung - 14/10/2020 Die Immuntherapie (ICI)  aktiviert Effektor-T-Zellen  und reduziert auf der anderen Seite regulatorische T-zellen, um den Tumor zu besiegen (schwarze Zellen). Die durch die Immuntherapie ausgelöste Lungenentzündung wird mit Steroidtherapie (Cortison) oder mit inhaliertem VIP (vasoaktives intestinales Peptid) behandelt. Unter VIP kommt es zur Dämpfung der Entzündung.

    Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
  • Press release - 08/10/2020

    New class of highly effective inhibitors protects against neurodegeneration

    Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-class-highly-effective-inhibitors-protects-against-neurodegeneration
  • KyooBe Tech GmbH - 08/10/2020 Scheme of the patented pump and roll system (LEEI technology).

    Next generation vaccine production

    For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
  • Press release - 07/10/2020

    Joining forces against SARS-CoV-2

    Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/joining-forces-against-sars-cov-2
  • Press release - 05/10/2020

    Solar-battery effect enables a new light-driven organic microswimmer to operate in the dark

    An interdisciplinary team of scientists at the Max Planck Institutes for Intelligent Systems and Solid State Research has developed a biocompatible microswimmer made of carbon nitride, which they can propel forward through light. The particle can also store solar energy similar to miniature solar cells equipped with batteries, and can thus also swim in the dark using the stored energy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/solar-battery-effect-enables-new-light-driven-organic-microswimmer-operate-dark
  • Freudenberg Filtration Technologies - 01/10/2020 Kfz-Innenraumfilter von Freudenberg Filtration Technologies scheiden zunächst Partikel und einen Großteil viraler Areosole ab und inaktivieren diese in ihrer letzten, mit Fruchtextrakten imprägnierten bio-funktionalen Schicht

    Coronavirus thwarted: with filters against aerosol spread

    Filter technology can effectively remove microorganisms such as the new coronavirus from aerosols. A team of experts at Freudenberg Filtration Technologies develops and produces filtration solutions that effectively reduce the spread of viruses in cars, industrial plants and public buildings. The company’s filter technology for reducing the viral load is a reliable method for enabling people to stay in closed rooms with a high density of people.

    https://www.gesundheitsindustrie-bw.de/en/article/news/coronavirus-thwarted-filters-against-aerosol-spread
  • Press release - 25/09/2020

    Bosch’s new rapid coronavirus test delivers reliable results in 39 minutes

    Bosch has developed a new rapid test for its Vivalytic analysis device to detect the SARS-CoV-2 pathogen. The test provides a reliable result in 39 minutes and is currently the fastest polymerase chain reaction (PCR) test worldwide.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/boschs-new-rapid-coronavirus-test-delivers-reliable-results-39-minutes
  • Organ failure due to fatty liver - 24/09/2020 AdobeStock_9729015_SciePro_Leber_Mensch.jpg

    HepaRegeniX develops an active substance for liver regeneration

    When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
  • Mosses for pharmaceutical production - 16/09/2020 Eleva_Bild_1.jpg

    Factor H as a therapeutic option for viral diseases - including COVID-19

    The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
  • Press release - 15/09/2020

    ELLIS inaugurates 30 research units at leading institutions across Europe

    At a virtual event on Tuesday, the European Laboratory for Learning and Intelligent Systems presented the broad scope of research its units will cover in the field of modern AI.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ellis-offizieller-start-der-30-forschungseinheiten-fuehrenden-institutionen-ganz-europa
  • Phytopharmaceuticals - 14/09/2020 Cannabisnet_Bild_11.jpg

    Medicinal cannabis to be grown in Germany

    Anyone who thinks hemp is just an inconspicuous plant, whose ingredients can be used, at best, as an intoxicant, can quickly be proven wrong. Besides being used as a valuable raw material for textiles and building materials, the plant has great potential as a medicinal drug. The CANNABIS-NET network, coordinated by the University of Hohenheim, has been set up to establish the basis for producing medicinal hemp in Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicinal-cannabis-be-grown-germany
  • Press release - 07/09/2020

    Cyber Valley launches Investor Network

    Europe’s largest AI research consortium attracts interest from some of the world’s most successful venture capital firms.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-gruendet-investor-network
  • Biochip systems - 02/09/2020 Hand hält einen Fett-Chip (Organ-on-a-Chip) in die Kamera. Gut zu sehen sind die Kammern und Kapillaren auf dem Mikrofluidik-System.

    Miniature organs with great potential

    Dr. Peter Loskill and his team at the Fraunhofer Institute in Stuttgart and the University Hospital of Tübingen are developing what is known as an "organ-on-a-chip" (OoC). An OoC is a microfluidic system that simulates small functional units of organ tissue. OoCs can be used in different ways: in basic and pharmaceutical research as well as in clinical research and application, where they might render many animal experiments…

    https://www.gesundheitsindustrie-bw.de/en/article/news/miniature-organs-great-potential
  • Press release - 01/09/2020

    Strengthening the immune system with small molecules

    Infections pose an increasing risk to hospitalized patients. In collaboration with a number of partners, the Fraunhofer IGB has developed a new therapeutic approach as part of the InnateFun project. Their strategy is to improve cells’ ability to defend themselves against harmful microorganisms by acting on their immune receptors. The researchers’ work on this therapeutic approach has reached the animal model stage.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/strengthening-immune-system-small-molecules
  • Press release - 31/08/2020

    Radiology researcher receives Humboldt Foundation Sofja Kovalevskaja Award

    Dr. André Martins from the Department of Radiology at the Tübingen University Hospitals is one of this year's recipients of the Alexander von Humboldt Foundation's Sofja Kovalevskaja Award.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/radiology-researcher-receives-humboldt-foundation-sofja-kovalevskaja-award
  • Innovative Therapies - 20/08/2020 Das Bild zeigt eine pipettierende Frau in Nahaufnahme. Symbolbild für analytische Dienstleistungen des portraitierten Unternehmens.

    Labor Dr. Merk is fully committed to viral therapies

    Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…

    https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
  • Press release - 12/08/2020

    New technology provides insight into the development of immune cells

    The entire range of our blood and immune cells are derived from hematopoietic stem cells. Yet which genes influence how they develop into the different cell types? Scientists from the German Cancer Research Center (DKFZ) have now developed a new technology to answer this question.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-technology-provides-insight-development-immune-cells
  • Press release - 11/08/2020

    Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan

    Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
  • Press release - 06/08/2020

    A bridge between artificial intelligence and the life sciences

    The great potential of artificial intelligence (AI) and machine learning for the life sciences – from basic research in biology to medical applications – has largely been neglected to date. A new research unit aims to support AI research in the life sciences and to forge international links with the activities in Heidelberg.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ellis-life-heidelberg-bridge-between-artificial-intelligence-and-life-sciences
  • CeGat GmbH - 06/08/2020 Cegat_Teaser.jpg

    Specific coronavirus antibody test for all

    Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all
  • Press release - 28/07/2020

    Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients

    Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received regulatory approval to start a clinical phase II trial with asunercept in COVID-19 patients in Russia. The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-start-european-clinical-phase-ii-trial-asunercept-covid-19-patients
  • TGU Varimol - 24/07/2020 Das Bild zeigt zwei kleine braune Chemikalienfläschchen, die alle nötigen Reagenzien für ihre Anwendung für Kunden der Varimol enthalten.

    Click chemistry for new medical procedures

    Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.

    https://www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
  • Press release - 23/07/2020

    Images from the inside of blood vessels

    Smallest 3D printed miniature endoscope in the world detects cholesterol plaques and thrombs inside human and mouse arteries.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/3d-bilder-aus-dem-inneren-von-adern
  • Microstructure Technology - 17/07/2020 eNase_Bild_4.jpg

    An electronic nose for many applications

    Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…

    https://www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
  • Stem cell therapy for regenerating intervertebral discs - 16/07/2020 800_Wisi_Focus_Web.jpg

    Ulm’s simulator has Europe’s back

    Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
  • Review article (new edition) - 08/07/2020 Arm in den mithilfe einer Spritze eine Impfung gespritzt wird.

    Immunology – at the forefront of medical progress

    Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress
  • Affimed GmbH - 01/07/2020 Schematische Darstellung der Kommunikation zwischen den Zellen der angeborenen und erworbenen Immunität. „innate cell engager“ aktivieren NK-Zellen und Makrophagen, die wiederum tumorspezifische T-Zellen stimulieren.

    "Innate cell engagers" to fight cancer

    In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innate-cell-engager-fighting-against-cancer
  • SICOS BW GmbH - 18/06/2020 SICOS BW ermöglicht zusammen mit dem Höchstleistungsrechenzentrum Stuttgart Unternehmen den Zugang zu Data Analytics, Smart Data und Big Data, KI und Virtual-Reality-Technologie.

    High-performance computing and data analytics to combat coronavirus

    In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.

    https://www.gesundheitsindustrie-bw.de/en/article/news/high-performance-computing-and-data-analytics-to-combat-coronavirus
  • Press release - 17/06/2020

    CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

    CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-Receives-Regulatory-Approval-from-German-and-Belgian-Authorities-to-Initiate-Phase-1-Clinical-Trial-of-its-SARS-CoV-2-Va
  • Press release - 15/06/2020

    German Federal Government invests 300 Million Euros in CureVac

    The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-federal-government-invests-300-million-euros-curevac
  • Innovations in the field of endoscopy - 08/06/2020 Computeranimation der Kamerapille im Dünndarm.

    Gastroscopies with pill cameras

    A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.

    https://www.gesundheitsindustrie-bw.de/en/article/news/magenspiegelung-kamerapille
  • Vaccine development - 02/06/2020 07777_de.jpg

    CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine?

    All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
  • Translational oncology - 26/05/2020 NCT_181204_3435.jpg

    Translation: driver of cancer medicine

    The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

    https://www.gesundheitsindustrie-bw.de/en/article/news/translation-driver-cancer-medicine
  • Material research - 25/05/2020 Das Team der Yuri GmbH in Meckenbeuren

    Reaching up into weightlessness – a start-up that enables commercial research experiments in space

    Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-up-into-weightlessness-a-start-up-enables-commercial-research-experiments-in-space
  • Trenzyme GmbH - 20/05/2020 Coronavirus im Elektronenmikroskop

    The SARS-CoV spike protein and its receptor

    The SARS-CoV-2 coronavirus uses a spike protein to bind to the ACE2 receptor on the cell surfaces of lung tissue. Additional cofactors are needed to allow the virus genome to penetrate human cells and multiply. Knowing these relationships can help understand the course of the infection and develop counterstrategies. To this end, the Constance-based company Trenzyme has produced a recombinant spike protein to support coronavirus research.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-sars-cov-spike-protein-and-its-receptor
  • Press release - 19/05/2020

    Cyber Valley welcomes five new members to its Start-Up Network

    Five new companies from the Stuttgart/Tübingen region in southwestern Germany have joined the Cyber Valley Start-Up Network. The innovative technologies and products of AmbiGate, Cytolytics, Mojin Robotics, plus10 and Tactai aim to achieve ground-breaking improvements in the fields of public health, manufacturing, and customer service. These start-ups join ten other companies that are already part of the Cyber Valley Start-Up Network.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-begruesst-fuenf-neue-mitglieder-seinem-start-network
  • Press release - 14/05/2020

    CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate

    CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-coronavirus-impfstoffkandidat-zeigt-dank-optimierter-mrna-plattform-positive-praeklinische-ergebnisse-bei-niedriger-dos
  • Press release - 13/05/2020

    Corona antibody tests from Reutlingen

    The NMI Reutlingen is currently tackling a major problem associated with antibody tests for the detection of COVID-19: false positive test results.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/corona-antikoerpertests-aus-reutlingen
  • Press release - 13/05/2020

    Drug counterfeiters use fear of corona epidemic

    Falsified chloroquine tablets identified in Africa - University of Tübingen supports local pharmacists in the analysis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/arzneimittelfaelscher-nutzen-angst-vor-corona-epidemie

Page 8 / 60

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 60
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search